公开(公告)号：US12252541B2

公开(公告)日：2025-03-18

申请号：US17053256

申请日：2019-06-26

Applicant: ABL BIO INC.

Inventor： Kyungjin Park ,  Hyejin Chung ,  Kyeongsu Park ,  Yangsoon Lee ,  Mikyung Chang ,  Jaehyoung Jeon ,  Youngkwang Kim ,  Junhyun Jeong ,  Jiseon Yoo ,  Yeunju Kim ,  Donghoon Yeom ,  Eunjung Kim ,  Bora Lee ,  Jinwon Jung

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/705

Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

公开(公告)号：US12122830B1

公开(公告)日：2024-10-22

申请号：US17057646

申请日：2019-05-23

Applicant: ABL Bio Inc.

Inventor： Yangsoon Lee ,  Juhee Kim ,  Kyungjin Park ,  Donghoon Yeom ,  Kyeongsu Park ,  Hyejin Chung ,  Yeunju Kim ,  Eunyoung Park ,  Ui-Jung Jung ,  Eunsil Sung ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  G01N2333/705 ,  G01N2333/912

Abstract: The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

公开(公告)号：US11891445B1

公开(公告)日：2024-02-06

申请号：US17057643

申请日：2019-05-24

Applicant: ABL Bio Inc.

Inventor： Kyeongsu Park ,  Yangsoon Lee ,  Hyejin Chung ,  Uijung Jung ,  Yong-Gyu Son ,  Sang-Jun Ha ,  Myeong Joon Kim ,  Eunyoung Park ,  Kyungjin Park ,  Eunsil Sung ,  Yeunju Kim ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

公开(公告)号：US20230405139A1

公开(公告)日：2023-12-21

申请号：US18209299

申请日：2023-06-13

Applicant: LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

Inventor： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61P35/00 ,  A61K47/6803 ,  C07K16/2803

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

Applicant: ABL Bio Inc.

Inventor： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

公开(公告)号：US11707533B2

公开(公告)日：2023-07-25

申请号：US16940326

申请日：2020-07-27

Applicant: LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

Inventor： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-Na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2803

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.